ES2112253T3 - Composiciones de farmaco de pequeña particula. - Google Patents

Composiciones de farmaco de pequeña particula.

Info

Publication number
ES2112253T3
ES2112253T3 ES90915978T ES90915978T ES2112253T3 ES 2112253 T3 ES2112253 T3 ES 2112253T3 ES 90915978 T ES90915978 T ES 90915978T ES 90915978 T ES90915978 T ES 90915978T ES 2112253 T3 ES2112253 T3 ES 2112253T3
Authority
ES
Spain
Prior art keywords
microspheres
microsphere
diameter
composition
particular pharmacy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90915978T
Other languages
English (en)
Inventor
Lisbeth Cavendish Cresce Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10665744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2112253(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Application granted granted Critical
Publication of ES2112253T3 publication Critical patent/ES2112253T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

UNA COMPOSICION DE SUMINISTRO DE DROGAS PARA EL SUMINISTRO INTRANASAL QUE CONSTA DE UNA PLURALIDAD DE MICROESFERAS BIOADHESIVAS Y UNA DROGA ACTIVA ASOCIADA A CADA UNA DE LAS MICROESFERAS, TENIENDO AL MENOS UN 90% EN PESO DE LAS MICROESFERAS UN DIAMETRO QUE VA DE 0,1 (MU)M A 10 (MU)M. LAS MICROESFERAS PUEDEN SER DE ALMIDON, GELATINA, DEXTRANO, COLAGENO O ALBUMINA. LAS DROGAS ADECUADAS INCLUYEN PEPTIDOS, COMO POR EJEMPLO INSULINA, E INGREDIENTES PARA VACUNAS ANTIGENICOS. LA COMPOSICION PUEDE CONTENER ADEMAS UN REFORZADOR DE LA ABSORCION. LAS MICROESFERAS SE ADMINISTRAN A LA CAVIDAD NASAL DE TAL MODO QUE EL PRODUCTO DEL CUADRADO DEL DIAMETRO DE LA MICROESFERA Y LA VELOCIDAD DE FLUJO SEA MAYOR DE 2000 (MU)M (AL CUADRADO) LITROS/MIN.
ES90915978T 1989-11-04 1990-11-01 Composiciones de farmaco de pequeña particula. Expired - Lifetime ES2112253T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8924935A GB2237510B (en) 1989-11-04 1989-11-04 Small particle drug compositions for nasal administration

Publications (1)

Publication Number Publication Date
ES2112253T3 true ES2112253T3 (es) 1998-04-01

Family

ID=10665744

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90915978T Expired - Lifetime ES2112253T3 (es) 1989-11-04 1990-11-01 Composiciones de farmaco de pequeña particula.

Country Status (10)

Country Link
EP (1) EP0500594B1 (es)
JP (1) JP2974409B2 (es)
AT (1) ATE162072T1 (es)
CA (1) CA2060176C (es)
DE (1) DE69031950T2 (es)
DK (1) DK0500594T3 (es)
ES (1) ES2112253T3 (es)
GB (1) GB2237510B (es)
GR (1) GR3026367T3 (es)
WO (1) WO1991006282A1 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
WO1993013753A1 (de) * 1992-01-17 1993-07-22 Alfatec-Pharma Gmbh Peptidarzneistoffe enthaltende pellets und ihre herstellung sowie deren verwendung
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
GB9221329D0 (en) * 1992-10-10 1992-11-25 Delta Biotechnology Ltd Preparation of further diagnostic agents
ES2068762B1 (es) * 1993-07-21 1995-12-01 Lipotec Sa Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion.
DE69535897D1 (de) 1994-03-07 2009-01-22 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
AU692565B2 (en) * 1994-06-16 1998-06-11 Pharmacia & Upjohn S.P.A. Bioadhesive starches and process for their preparation
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
AU4990696A (en) * 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
FR2732605B1 (fr) * 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
US6344202B1 (en) 1996-07-12 2002-02-05 University Of Manitoba DNA immunization against chlaymdia infection
US20070092563A1 (en) 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
KR100796220B1 (ko) * 1998-06-29 2008-01-21 넥타르 테라퓨틱스 미립자 전달 시스템 및 사용 방법
CA2341732C (en) * 1998-08-26 2008-08-19 Teijin Limited Powder composition for nasal administration
US6264975B1 (en) * 1998-10-20 2001-07-24 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
US6811783B1 (en) 1999-09-07 2004-11-02 Aventis Pasteur Limited Immunogenic compositions for protection against chlamydial infection
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU2002229434A1 (en) * 2001-01-29 2002-08-12 Bernard B. Fresco Controlled release microsphere system for administration of drug to the eye
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
DK2068825T3 (da) 2006-10-04 2011-05-16 M & P Patent Ag Kontrolleret frisætningstilførselssystem til nasal påføring af neurotransmittere
EP2471518B1 (en) 2009-05-18 2017-08-23 Sigmoid Pharma Limited Composition comprising oil drops
EP2464341B1 (en) * 2009-08-12 2022-07-06 Sublimity Therapeutics Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130040923A1 (en) 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
KR20160112005A (ko) 2014-01-27 2016-09-27 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 친수성 활성 화합물의 나노캡슐화
RU2014120626A (ru) * 2014-05-22 2015-11-27 Владимир Андреевич Сабецкий Инсулинсодержащий препарат пролонгированного действия

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1520247A (en) * 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1520248A (en) * 1975-07-24 1978-08-02 Fisons Ltd Sodium cromoglycate containing medicament
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
EP0187433B1 (en) * 1983-08-01 1990-12-27 Teijin Limited Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity
DE3341001A1 (de) * 1983-11-12 1985-05-23 Krause, Hans Jürgen Nanopartikel aus bioabbaubarem, synthetischem material, verfahren zu deren herstellung und ihre anwendung
EP0248051A1 (en) * 1985-11-29 1987-12-09 FISONS plc Pharmaceutical composition including sodium cromoglycate
GB8712176D0 (en) * 1987-05-22 1987-06-24 Cosmas Damian Ltd Drug delivery system
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system

Also Published As

Publication number Publication date
JPH05501408A (ja) 1993-03-18
DK0500594T3 (da) 1998-09-14
JP2974409B2 (ja) 1999-11-10
ATE162072T1 (de) 1998-01-15
DE69031950T2 (de) 1998-05-28
EP0500594B1 (en) 1998-01-14
DE69031950D1 (de) 1998-02-19
GB2237510A (en) 1991-05-08
WO1991006282A1 (en) 1991-05-16
EP0500594A1 (en) 1992-09-02
GB2237510B (en) 1993-09-15
GR3026367T3 (en) 1998-06-30
CA2060176A1 (en) 1991-05-05
CA2060176C (en) 2001-01-09
GB8924935D0 (en) 1989-12-28

Similar Documents

Publication Publication Date Title
DK0500594T3 (da) Lægemiddelsammensætninger indeholdende små partikler
DE69428040D1 (de) Orale darreichungsform
CA2258095A1 (en) Tetrahydrolipstatin containing compositions
RU92016471A (ru) Твердая непористая микросфера, способ ее получения и применение в фармакологическом препарате
DE69434963D1 (de) Selektiv auf die leber wirkende pharmazeutisch aktive substanz
PT731688E (pt) Formulacoes de farmacos em aerossol para utilizacao com propulsores sem cfc
KR910004180A (ko) 저작성 약제학적 정제를 제조하기 위한 회전과립화 공정 및 맛을 은폐하기 위한 피복공정
ES2159524T3 (es) Preparacion farmaceutica para administrarse en el interior de las vias respiratorias.
BR9909394A (pt) Composição de aerossol, composição farmacêutica, recipiente, dispositivo de inalação, processo para preparar uma composição de aerossol, mistura de um primeiro material particulado, e, processo para administrar um medicamento particulado
BRPI9509286B8 (pt) microcápsulas medicamentosas e/ou nutricionais para administração per si.
CA2116563A1 (en) Dry gel pharmaceutical composition
CA2291994A1 (en) Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents
DE3678661D1 (de) Arzneimittel mit langsamer wirkstofffreisetzung.
AU6829287A (en) Stabilised formulations of alpha-interferon
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
BR9401199A (pt) Preparados de medicamentos, processo para a preparação de um preparado de medicamento, processo para a preparação de uma formulação de medicamento.
KR880004805A (ko) 분무건조된 아세트아미노펜
ID22763A (id) Komposisi penstabil tibolon
DE69622739D1 (de) Pharmazeutische zubereitung mit schneller freisetzung
JPS6450821A (en) Pharmacological composition and preparation
SE9403905D0 (sv) New formulations
RU93027376A (ru) Получение таблетки, содержащей интерферон-альфа, для энтерального применения и ее состав
MY104088A (en) Peptide-drugs compositions containing (alpha)-aminoboroic acid derivatives.
ATE110564T1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren.
EP0362731A3 (de) Verfahren zur Herstellung von Arzneimittelwirkstoff-Partikeln mit verbesserten Fliess-, Lager- und Formulierungseigenschaften sowie Arzneimittel, die diese Arzneimittelwirkstoff-Partikeln enthalten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 500594

Country of ref document: ES